Carmell Therapeutics Corp... (CTCX)
0.20
0.01 (2.77%)
At close: Mar 07, 2025, 3:55 PM
2.77% (1D)
| Bid | 0.2 |
| Market Cap | 5.94M |
| Revenue (ttm) | -5.33M |
| Net Income (ttm) | -11.28M |
| EPS (ttm) | 0.48 |
| PE Ratio (ttm) | 0.41 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.21 |
| Volume | 63,382 |
| Avg. Volume (20D) | 8,229,021 |
| Open | 0.20 |
| Previous Close | 0.19 |
| Day's Range | 0.19 - 0.21 |
| 52-Week Range | 0.17 - 3.00 |
| Beta | 0.51 |
About CTCX
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was foun...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 23, 2021
Employees 9
Stock Exchange NASDAQ
Ticker Symbol CTCX
Website https://www.carmellrx.com
3 months ago
+147.98%
Carmell Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
3 months ago
+26.2%
Carmell shares are trading higher after the announced it has entered securities purchase agreement with new and existing investors.
